Roche touts PhIII results of Avastin combo in brain cancer

Roche ($RHHBY), the biggest cancer drug provider in the world, has made progress in building on its blockbuster franchise for the anti-tumor drug Avastin with results of a Phase III study that shows the drug used in combination with radiation and chemotherapy improved progression-free survival in patients newly diagnosed with glioblastoma. Avastin is already approved for treatment of brain cancer as a standalone agent, but the latest results boost the company's case for using the drug with standard approaches to combat the aggressive tumors early. Article

 

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.